Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13450248 | 0.87 | TDP1 (0.58) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6935345 | 0.86 | MEN1 (0.70) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL259296 | 0.83 | KMT2A (0.80) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL24485978 | 0.83 | SIRT2 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL22024851 | 0.83 | FADS1 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL22024849 | 0.83 | HDAC6 (0.64) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL13342538 | 0.82 | RAB9A (0.68) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL259362 | 0.82 | MEN1 (0.73) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10731336 | 0.82 | KDM4E (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL26322715 | 0.81 | ALDH1A1 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MEN1 3330/4885KMT2A 1722/4885SMN1; SMN2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.